A Clinical Commitment
SKYTROFA® has been studied in over 300 children with GHD, including treatment‑naïve and treatment-experienced patients1‑3
SKYTROFA phase 3 program in pediatric GHD1‑4
Experience Growth
Once-weekly SKYTROFA: Demonstrated higher LS mean AHV at week 52 in treatment-naïve children compared with a daily somatropin1,2
LS mean AHV and height SDS changes from baseline at week 52: Once-weekly SKYTROFA versus daily somatropin1,2*
- The treatment difference in LS mean AHV with SKYTROFA compared with daily somatropin was 0.9 cm/year1,2
- 95% CI of 0.2 to 1.5 cm/year1,2
- The weekly dose of hGH was equivalent to 0.24 mg hGH/kg/week for both SKYTROFA and daily somatropin1
- The change in mean (SD) bone age from baseline to week 52 was similar with SKYTROFA (1.36 [0.87] years) and daily somatropin (1.35 [0.72] years)5
Sustained growth was achieved with SKYTROFA in treatment-naïve patients6
Patients treated with SKYTROFA had a greater increase from baseline in height SDS† compared with patients treated with a daily somatropin2‡
Once-weekly SKYTROFA makes dosing easy for patients and their healthcare professionals
LEARN MORE ABOUT CONVENIENT DOSING